Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
flutoltropoate (18F)
- Development stage
- Unknown
- Lead developer
- GE Healthcare
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
flutoltropoate (18F) (formerly known as [18F]GEH300022 or [18F]LBT-999) is a fluorine-18 labeled phenyltropane derivative that acts as a highly selective and high-affinity PET radiotracer targeting the dopamine transporter (DAT). Developed by GE HealthCare following its acquisition of Zionexa, flutoltropoate (18F) is designed for the non-invasive visualization and quantification of presynaptic dopaminergic innervation in the brain. It is primarily in Phase III clinical development as a diagnostic imaging agent to differentiate Parkinsonian disorders (such as Parkinson's disease) from essential tremor. It offers a faster imaging protocol and higher spatial resolution compared to traditional SPECT imaging agents like [123I]ioflupane (DaTSCAN).
- Other names
- [18F]GEH300022[18F]LBT-999[18F]LBT999F-18 flutoltropoateF18 flutoltropoateF 18 flutoltropoateFluorine 18 flutoltropoateFluorine18 flutoltropoateFluorine-18 flutoltropoateLBT-999-PETLBT999-PETLBT 999-PETLBT999-[18F]flutoltropoate F-18flutoltropoate-Fluorine 18flutoltropoate-Fluorine18flutoltropoate-Fluorine-18
02
Targets
DAT (Dopamine plasma membrane transport protein)
Beyond the preview
Go deeper on flutoltropoate (18F).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on flutoltropoate (18F).